GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Return-on-Tangible-Asset

Tibet Aim Pharm (SZSE:002826) Return-on-Tangible-Asset : 8.17% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Tibet Aim Pharm's annualized Net Income for the quarter that ended in Mar. 2025 was ¥75.2 Mil. Tibet Aim Pharm's average total tangible assets for the quarter that ended in Mar. 2025 was ¥919.6 Mil. Therefore, Tibet Aim Pharm's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 8.17%.

The historical rank and industry rank for Tibet Aim Pharm's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:002826' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.68   Med: 5.19   Max: 16.98
Current: 4.06

During the past 12 years, Tibet Aim Pharm's highest Return-on-Tangible-Asset was 16.98%. The lowest was 1.68%. And the median was 5.19%.

SZSE:002826's Return-on-Tangible-Asset is ranked better than
56.81% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.68 vs SZSE:002826: 4.06

Tibet Aim Pharm Return-on-Tangible-Asset Historical Data

The historical data trend for Tibet Aim Pharm's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Return-on-Tangible-Asset Chart

Tibet Aim Pharm Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.02 5.28 5.19 1.68 5.18

Tibet Aim Pharm Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.52 5.28 0.97 1.82 8.17

Competitive Comparison of Tibet Aim Pharm's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Return-on-Tangible-Asset falls into.


;
;

Tibet Aim Pharm Return-on-Tangible-Asset Calculation

Tibet Aim Pharm's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=45.929/( (885.168+889.105)/ 2 )
=45.929/887.1365
=5.18 %

Tibet Aim Pharm's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=75.176/( (889.105+950.083)/ 2 )
=75.176/919.594
=8.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Tibet Aim Pharm  (SZSE:002826) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Tibet Aim Pharm Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 610000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic diseases such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Xu Ke Director
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm Headlines

No Headlines